RxDoctor Payments Data

Lisa Beavers, NP

Family · Aberdeen, MDNPI 1700373289

Payments from drug & device makers

$2,114in general payments, 2019–2025

Across 96 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$652
  • AstraZeneca$485
  • Astellas Pharma US Inc$190
  • Exact Sciences$161
  • Dexcom, Inc.$154
  • Pfizer$138
  • plus $335 from 8 others

What the payments were for

  • Food & beverage$1,98394%
  • Education$1316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,114 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$49,791
Medicare patients
350
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$48,009
MounjaroTirzepatide16$37,165
JardianceEmpagliflozin34$34,973
JanuviaSitagliptin Phosphate14$21,936
EliquisApixaban14$16,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,722
Rosuvastatin Calcium175$3,461
Atorvastatin Calcium206$2,320
Gabapentin62$1,356
Levothyroxine Sodium120$1,344
Metoprolol Succinate83$1,254
Amlodipine Besylate139$1,052
Bupropion XlBupropion Hcl18$1,010
Omeprazole79$1,000
Sertraline Hcl56$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$652$48,00929 claims
Lilly USA, LLCMounjaro$114$37,16516 claims
PfizerEliquis$138$16,12714 claims
AbbVieSynthroid$29$55515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Aberdeen

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →